Abstract

ObjectiveTo assess the overlap of and differences between quantitative muscle MRI and ultrasound in characterizing structural changes in leg muscles of facioscapulohumeral muscular dystrophy (FSHD) patients.MethodsWe performed quantitative MRI and quantitative ultrasound of ten leg muscles in 27 FSHD patients and assessed images, both quantitatively and visually, for fatty infiltration, fibrosis and edema.ResultsThe MRI fat fraction and ultrasound echogenicity z-score correlated strongly (CC 0.865, p < 0.05) and both correlated with clinical severity (MRI CC 0.828, ultrasound CC 0.767, p < 0.001). Ultrasound detected changes in muscle architecture in muscles that looked normal on MRI. MRI was better in detecting late stages of fatty infiltration and was more suitable to assess muscle edema. Correlations between quantitative and semi-quantitative scores were strong for MRI (CC 0.844–0.982, p < 0.05), and varied for ultrasound (CC 0.427–0.809, p = 0.026–p < 0.001).ConclusionsQuantitative muscle MRI and ultrasound are both promising imaging biomarkers for differentiating between degrees of structural muscle changes. As ultrasound is more sensitive to detect subtle structural changes and MRI is more accurate in end stage muscles and detecting edema, the techniques are complementary. Hence, the choice for a particular technique should be considered in light of the trial design.

Highlights

  • Muscle imaging complements the clinical assessment of muscle disorders

  • There was a strong correlation between the degree of fatty infiltration on MRI and the ultrasound echo intensity

  • A study on Facioscapulohumeral muscular dystrophy (FSHD) patients using muscle biopsies from tibialis anterior and vastus lateralis muscles that appeared normal on MRI, showed mild to moderate fibrosis in 11 of 17 biopsies (65%)

Read more

Summary

Introduction

Muscle imaging complements the clinical assessment of muscle disorders. It reveals patterns and severity of muscle involvement that can help guide diagnosis and track disease progression [1]. Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive inherited muscle disorder [2]. Recent insights in its pathogenic mechanism are expected to be translated into targeted therapies soon [3, 4]. Clinical trials are expected in the upcoming years, requiring (imaging) biomarkers for the assessment of muscle. M. van Engelen and Nens van Alfen contributed to the manuscript

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call